Pure Global
NCT06299631

Endoscopic Relapse Risks Evaluation After Ileocolic Resection for Crohn's Disease

Endoscopic Relapse Risk Factors After Ileocolic Resection on Crohn's Disease Patients in the Biologic Era
University Hospital, Montpellier·ClinicalTrials.gov·procedureCompleted
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Crohn's Disease
Drug/Device/Intervention
Ileocolic resection
Study type
Observational
Intervention type
procedure
Sponsor & location
Primary sponsor
University Hospital, Montpellier
Location
Montpellier, France
Timeline & enrollment
Phase
N/A
Start date
Jan 01, 2015
End date
Dec 01, 2023
Enrollment
133 participants
Primary outcome

Endoscopic recurrence rate

Summary

Aim of the study:
 
 To evaluate risk factors of endoscopic relapse after ileocolic resection in a cohort of
 Crohn's disease patients treated with anti-TNF agents.
 
 Methods:
 
 From 2014 to 2022, all consecutive patients who underwent ileocolic resection for Crohn's
 disease treated with anti-TNF agents in two referral tertiary center were prospectively
 collected.
 
 Considering exclusion criteria, data from 114 patients were analyzed. The cohort was
 separated into 2 groups according to study period.
 
 Short and long-term outcomes were compared between the two groups.
 
 Primary outcome:
 
 Endoscopic recurrence (defined as i2 lesions according to Rutgeerts classification) 6
 months after surgery

ICD-10 classifications
Crohn disease, unspecifiedOther Crohn diseaseCrohn disease of large intestineCrohn disease [regional enteritis]Crohn disease of small intestine
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06299631
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06299631 through Pure Global AI's free database. This phase not specified trial is sponsored by University Hospital, Montpellier and is currently Completed. The study focuses on Crohn's Disease. Target enrollment is 133 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.